Hancock Whitney is set to report its Q3 2026 earnings on October 20, with analysts forecasting earnings per share between $1.65 and $1.66 and revenue estimates from $418.85 million to $422 million. Despite year-over-year growth projections, indicators suggest the bank may miss earnings expectations. The bank trades at a trailing P/E of 14.44 and a price-to-sales ratio of 3.04, providing context for investors comparing regional banks. The upcoming report and management commentary will be key for assessing the bank's current performance and outlook.
Hancock Whitney Q3 2026 earnings preview provides context for financial sector investors. For readers following US financial stocks, here is Pluang's market snapshot as of Oct 20, 2026 23:02 WIB: Out of 142 priced financials-sector US stocks, 131 rose and 11 fell today. Notable movers include BMNR at USD 22.86 (+5.98%), NU at USD 15.31 (+5.55%) with 100% buy orders, and RKT at USD 11.27 (+5.23%).
Synchrony Financial reported Q3 2026 earnings per share of $2.68 and revenue of $4.91 billion, both exceeding analyst expectations. However, net profit fell to $892 million from $1.1 billion the previous year due to higher operating costs, even as cr...
In September 2026, New York State's housing inventory increased by 9.8% year-over-year, reaching 35,294 homes available for sale. Despite this rise in supply, home prices continued to grow, with the median sales price up 5.9% to $450,000 compared to ...
The Europe Electronic Health Record (EHR) market is projected to grow from $8.05 billion in 2024 to $15.37 billion by 2031, at a compound annual growth rate of 9.9%. Growth is fueled by increasing EHR adoption, government digital health programs, and...
EssilorLuxottica reported a 9.0% increase in revenue for Q3 2026, reaching €7,486 million, with a 7.2% rise at constant exchange rates. Growth was broad-based, with strong double-digit increases in Asia-Pacific and the Direct to Consumer segment up 1...
Goldman Sachs has increased its price target for Eli Lilly stock to $1,413, signaling an 8.87% potential upside amid strong revenue growth in the competitive weight-loss drug market. Despite projected revenue rising 25.59% to $22.11 billion, earnings...
